Source: Mediterranee Infection

Abstract

Background.

SARS-CoV-2 infection can cause significant mortality among dependant elderly residents living within medical retirements homes. Objectives. To report the results of SARS-CoV-2 PCR-based screening campaigns conducted in dependent elderly resident in retirement homes in Marseille, France and the follow-up of positive cases.

Methods.

Data of 1690 elderly residents and 992 member staffs were retrospectively collected through interview of the medical team of 23 retirement homes and electronic health recording system of the hospital.

Results.

Elderly residents were predominantly female (64.8%) with a mean age of 83 years old. SARS-CoV-2 detection in residents (226, 13.4%) was significantly higher than in staff members (87, 8.8%), with p=4.10-4 . Of 226 infected residents, 37 (16.4%) were detected on a case-by-case basis because of COVID-19 symptoms and 189 (83.6%) were detected through mass screening; 84.0% had possible COVID-19 symptoms, including respiratory symptoms and signs (48.5%) and fever (47.2%); 118 (52.2%) patients received a course of oral hydroxychloroquine and azithromycin (HCQ-AZ) for at least 3 days; and 47 (20.8%) died. In multivariate, death rate was positively associated with being male (31.5% vs. 13.4%, OR=4.33, p<10-4 ) and being older than 85 years (26.1% vs. 15.7%, OR=3.01, p=0.005) and negatively associated with being diagnosed through mass screening (16.9%, vs. 40.5%, OR=0.20, p<10-4 ) and receiving HCQ-AZ treatment for at least 3 days (14.4% vs. 27.8%, OR=0.41, p=0.017).

Conclusion.

Our data shows that early diagnosis and care of COVID-19 patients at retirement homes can be effective in saving lives.





Related:

61 studies (37 peer reviewed) Early treatment studies are very positive – COVID deaths: 621, 206

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »